Related Experiment Videos
Lymph node metastasis from melanoma with an unknown primary site.
1Division of Clinical Oncology, The Netherlands Cancer Institute, (Antoni van Leeuwenhoek Huis), Amsterdam.
The British Journal of Surgery
|June 1, 1990
Summary
Surgically treating melanoma with unknown primary and lymph node metastasis shows a 49% disease-free survival at 5 and 10 years. Radical node dissection is crucial for improving patient prognosis.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- Melanoma with unknown primary and lymph node metastasis presents a unique clinical challenge.
- Understanding prognostic factors is vital for optimizing treatment strategies in these cases.
Purpose of the Study:
- To analyze the outcomes of surgical treatment for melanoma with lymph node metastasis of unknown primary.
- To identify prognostic factors influencing survival in this patient cohort.
Main Methods:
- Retrospective analysis of 26 patients surgically treated between 1961 and 1986.
- Evaluation of actuarial disease-free survival rates and prognostic variables.
Main Results:
- Overall 5- and 10-year actuarial disease-free survival was 49%.
- Favorable prognostic factors included female sex, single lymph node involvement, and metastasis to the groin or axilla.
- Multifactorial analysis revealed only cervical metastasis site as a significant predictor of survival (P = 0.005).
Conclusions:
- Radical lymph node dissection is essential for patients with melanoma of unknown primary presenting with lymph node metastasis.
- Survival rates in this series are comparable to or better than those with known primary melanoma, underscoring the importance of aggressive surgical management.